Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate

This article was originally published here

The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial

The post Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply